Cingulate INC 8-K filings

Cingulate Inc. reported its Q1 2025 financial results, highlighted by a Pre-NDA meeting for CTx-1301 and a grant to accelerate CTx-2103 development.

Cingulate Inc. receives a $3 million grant from a private foundation to accelerate the development of CTx-2103 (buspirone) for anxiety treatment.

Cingulate Inc. reports positive financial results for 2024, highlighted by increased working capital and progress towards NDA submission for its lead ADHD asset, CTx-1301.

Cingulate Inc. reports positive safety results from Phase 3 trials for CTx-1301, its lead candidate for ADHD treatment, and is on track to file for FDA approval in mid-2025.

Cingulate Inc. announces the dismissal of an allegation against CEO Shane Schaffer, with the Board reaffirming its support.

Cingulate Inc. has amended the employment agreement of its Executive Vice President and Chief Medical Officer, Matthew N. Brams, changing his compensation structure to an annual base salary and annual equity grants.

Cingulate Inc. has completed its final FDA-required food effect study for CTx-1301, an ADHD treatment, with no serious adverse events reported and a New Drug Application submission targeted for mid-2025.

Cingulate Inc. has finalized a $5 million financing agreement through a promissory note to support its operations and extend its cash runway into the fourth quarter of 2025.

Cingulate Inc. announced its Q3 2024 financial results, highlighting a $19.5 million increase in working capital and progress towards a mid-2025 NDA submission for its lead ADHD drug, CTx-1301.

Cingulate Inc. has increased the maximum offering price of its common stock under an existing agreement and filed a prospectus supplement for an additional $8.34 million.

Cingulate Inc. has successfully raised approximately $11.7 million in capital, extending its operational runway through the second quarter of 2025 and targeting an NDA filing for CTx-1301 in mid-2025.

Cingulate Inc.'s CEO and Chairman, Shane Schaffer, was charged with aggravated domestic battery on September 23, 2024, but the board has expressed its full support for him to continue leading the company.

Cingulate Inc. has reinstated executive salaries, initiated the final FDA study for its ADHD drug CTx-1301, and raised over $10 million in additional capital.

Cingulate Inc. has been notified by Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement.

Cingulate Inc. has increased the maximum offering price of its common stock under an existing agreement and filed a prospectus supplement for an additional $3.87 million.

Cingulate Inc. announces that it has 2,179,755 shares of common stock outstanding as of August 28, 2024, following recent sales under its At The Market Offering Agreement and purchase agreement.

Cingulate Inc. stockholders approved the issuance of shares underlying certain warrants and a proposal to adjourn the special meeting if necessary.

Cingulate Inc. has increased its share offering and secured a European patent for its lead ADHD treatment, CTx-1301.

Cingulate Inc. reports positive progress in the development of CTx-1301, including FDA clearance to file for marketing approval, and a $1.6 million capital raise through a warrant inducement.

Cingulate Inc. received an extension from Nasdaq to meet minimum bid price requirements and will implement a 1-for-12 reverse stock split on August 9, 2024.

Cingulate Inc. stockholders approved a reverse stock split proposal and an adjournment proposal at a special meeting held on July 30, 2024.

Cingulate Inc. has entered into agreements for the immediate exercise of existing warrants, generating $1.86 million in gross proceeds, and will issue new warrants in a private placement.

Cingulate Inc. has received a delisting notice from Nasdaq due to its failure to maintain a minimum share price of $1.00, and the company intends to request a hearing to appeal the decision.

Cingulate Inc. stockholders approved an amendment to the company's equity incentive plan, increasing the authorized shares by 1,250,000, and elected new Class III directors at their annual meeting on June 11, 2024.

Cingulate Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement and will be subject to a one-year monitoring period.

Cingulate Inc. believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement, but the company's listing status remains uncertain pending final determination.

Cingulate Inc. reported its first quarter 2024 financial results, highlighted by a $10 million increase in stockholders' equity and progress towards a planned NDA filing for CTx-1301 in the first half of 2025.

Cingulate Inc. reported its 2023 financial results, highlighted by $17.8 million in capital raised and positive Phase 3 clinical data for its lead ADHD drug candidate.

Cingulate Inc. has increased its at-the-market offering and amended warrants, raising the potential offering to $8.47 million and adjusting warrant terms.

Cingulate Inc. has been granted an extension to maintain its Nasdaq listing through May 13, 2024, after regaining compliance with board composition requirements.